Search
Cintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual
Bexarotene
go.drugbank.com/drugs/DB00307ApprovedInvestigationalBexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Glatiramer
go.drugbank.com/drugs/DB05259ApprovedInvestigational[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … Glatiramer acetate exhibits several immunomodulatory effects and reduces the relapse rate of relapsing-remitting multiple sclerosis (RRMS) by 30%.
Oportuzumab monatox
go.drugbank.com/drugs/DB05319InvestigationalVB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells.
SNS-314
go.drugbank.com/drugs/DB06134InvestigationalSNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.
Sertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnSerdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia.
Pegzilarginase
go.drugbank.com/drugs/DB14780Approved[L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the
BacTRL-spike
go.drugbank.com/drugs/DB15811InvestigationalBacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. … The vaccine was developed by Symvivo Corporation.
Sulfanilamide
go.drugbank.com/drugs/DB00259ApprovedWithdrawnSulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.
Obinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521]